The Private Ledger: Hypocrisy, Capture, and Moral Bankruptcy in America’s Kidney Industry

Every year, the American kidney system asks for absolute trust. It asks grieving families to give the bodies of the people they love. It asks hundreds of thousands of patients to sit through treatment, keep their phones charged, and wait. It asks taxpayers to fund nearly all of it. And every year, behind the language of the gift, a private ledger records what actually happens: kidneys placed outside the published list, offers declined without the patient’s knowledge, donors whose time of death was never documented, organs lost in commercial cargo holds, and billions of public dollars flowing to institutions that face almost no consequence for failure.

The Private Ledger reads that ledger aloud.

This is not a memoir, and it is not a polite policy brief written to be acceptable to the institutions it examines. It is a 229-page investigative and existential indictment, built the way an auditor builds a finding: one verified data point at a time. Every charge is tied to a federal investigation, an Inspector General audit, a Justice Department filing, a peer-reviewed study, a congressional inquiry, or the organizations’ own tax returns. Where a matter is an allegation, the book says so. Where an organization has denied a finding, the book records the denial. Then it sets the public statements of named leaders beside the documented record of their institutions, chapter by chapter, in a section called the Hypocrisy Ledger.

The book is organized as an indictment in fourteen counts across seven parts. Part One, The Line, exposes how out-of-sequence kidney placement grew from 2.2 percent of deceased-donor kidney transplants in 2020 to nearly one in four by 2024. It shows how roughly 85,000 waitlisted patients who had received at least one kidney offer died or were removed from the list without a transplant, and how a donor grading formula penalized organs from Black donors and hepatitis C positive donors for years after the science had moved.

Part Two, The Donor, confronts the federal review in Kentucky that found procurement beginning on patients who showed signs of life. It examines the contested procurement technique that the nation’s largest physician specialty organization urged be paused, and the tissue economy that turns a single donor into dozens of grafts and hundreds of millions of dollars in nonprofit revenue.

Part Three, The Money, follows a September 2026 Inspector General finding that Medicare paid an estimated $380 million over six years for organs never transplanted into Medicare patients. It documents the executive compensation, reserves, parade floats, and sports tickets that drew bipartisan congressional condemnation.

Part Four, The Body in the Chair, examines federal and state allegations that more than half of 2,303 angioplasties performed on 60 dialysis patients were medically unnecessary. It also covers a national patient organization’s report that dialysis providers withheld a hormone therapy until laboratory values far exceeded guideline ranges.

Part Five, The Clock, tracks kidneys shipped as commercial cargo in a system where no federal agency was required to monitor how organs traveled.

Part Six, The Machinery of Capture, reveals how patient advocacy was funded and deployed by the dialysis duopoly. A kidney charity drawing roughly four-fifths of its donor base from two corporations joined them in federal court to nullify a law capping their reimbursement. More than $1.4 billion in settlements and penalties failed to change an industry too dominant to exclude, and $233 million in political spending defeated California measures requiring on-site clinicians, infection reporting, and ownership disclosure.

Part Seven, The Cure Left in the Cold, names the constraint the entire system has ignored: the viability of the organ over time. It contrasts a national French trial of a biologic oxygen carrier for kidney preservation with an American system that left more than one in four recovered kidneys unused in 2023, machine perfused barely half, and offers no regulatory pathway for Biologic Hemoglobin Oxygen Carrier (BHOC) technology in organ preservation.

What sets this book apart is its method. Every chapter applies the Lean Six Sigma DMAIC cycle to a broken process, defining the patient rather than the institution as the customer. The evidence is illustrated with run charts, Pareto analysis, process funnels, heat maps, swimlane timelines, and a full-page System Constraint Map of the entire kidney value stream. Every chapter also asks what these failures mean for the human beings inside them, drawing on Kafka, Kierkegaard, Arendt, Levinas, Foucault, Heidegger, Titmuss, Mauss, Goffman, and others to give the statistics their full existential weight. The book closes with an Accountability Roster that names who held the authority to change the system, and an eight-point agenda of structural demands, each paired with a measurable control.

Inside you will find a designed cover and part openers, a full table of contents, 27 original data visualizations, key takeaways for every chapter, a glossary of Lean Six Sigma terms, a note on sources and allegations, and more than 130 references.

The Private Ledger is written for patients and care partners who were told to trust the process, and for donor families who deserve to know what happened to their gift. It is written for journalists, legislators, regulators, and policy staff who need a verified record in one place, and for clinicians, researchers, and quality professionals who suspect the system has been measuring the wrong things. It is a perspicacious, unflinching, and meticulously sourced reckoning with an industry that has grown comfortable behind the halo of the gift.